Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

被引：33

作者：

Barnes, Theresa ^{[1
]}

Moots, Robert ^{[1
]}

机构：

[1] Univ Liverpool, Acad Rheumatol, Liverpool L69 3BX, Merseyside, England

来源：

INTERNATIONAL JOURNAL OF NANOMEDICINE | 2007年 / 2卷 / 01期

基金：

英国医学研究理事会;

关键词：

certolizumab pegol; TNF alpha; rheumatoid arthritis; nanomolecule;

D O I：

10.2147/nano.2007.2.1.3

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

Anti-TNF alpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNF alpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNF alpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.

引用

页码：3 / 7

页数：5

共 17 条

[11] Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis - Results from the British Society for Rheumatology Biologics Register [J].

Hyrich, Kimme L. ;

Symmons, Deborah P. M. ;

Watson, Kath D. ;

Silman, Alan J. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (06) :1786-1794

[12] CDP-870 (certolizumab) in rheumatoid arthritis [J].

Kaushik, VV ;

Moots, RJ .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (04) :601-606

[13] TRANSGENIC MICE EXPRESSING HUMAN TUMOR-NECROSIS-FACTOR - A PREDICTIVE GENETIC MODEL OF ARTHRITIS [J].

KEFFER, J ;

PROBERT, L ;

CAZLARIS, H ;

GEORGOPOULOS, S ;

KASLARIS, E ;

KIOUSSIS, D ;

KOLLIAS, G .

EMBO JOURNAL, 1991, 10 (13) :4025-4031

[14]

KEYSTONE E, 2001, 3 AM COLL RHEUM ANN

[15]

Mehvar R, 2000, J PHARM PHARM SCI, V3, P125

[16] Biologic therapy in clinical practice: enthusiasm must be tempered by caution [J].

Moots, R ;

Taggart, A ;

Walker, D .

RHEUMATOLOGY, 2003, 42 (05) :614-616

[17] Anti-TNF-α therapies:: they are all the same (aren't they?) [J].

Mpofu, S ;

Fatima, F ;

Moots, RJ .

RHEUMATOLOGY, 2005, 44 (03) :271-273

← 1 2 →